drugset / Trial / NCT04575467
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Non-randomizedSequentialOpen-labelTreatment
Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.
Timeline
- Start
- 2020-12-09
- Primary completion
- 2021-11-15
- Completion
- 2021-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 320 mg | Other |
| Subject | CBL-514 | Unknown | 480 mg | Other |
| Subject | CBL-514 | Unknown | 640 mg | Other |
| Subject | CBL-514 | Unknown | 800 mg | Other |
Indications
No indication recorded.